Drugs / rIL-2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02650648 Background | Jan 2016 → Jul 2025 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rIL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02650648 ↗ |
| Route | Subcutaneous | “rIL-2 is administered subcutaneously” NCT02650648 ↗ |